{"id":47853,"date":"2022-06-12T12:30:00","date_gmt":"2022-06-12T07:00:00","guid":{"rendered":"https:\/\/tradebrains.in\/features\/?p=47853"},"modified":"2022-06-12T10:45:41","modified_gmt":"2022-06-12T05:15:41","slug":"3-pharma-stocks-with-more-than-34-upside-potential","status":"publish","type":"post","link":"https:\/\/tradebrains.in\/features\/3-pharma-stocks-with-more-than-34-upside-potential\/","title":{"rendered":"Stock Recommendation: 3 Pharma Stocks with More than 34% Upside Potential"},"content":{"rendered":"<div class=\"trade-content_2\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-3374412498\"><p><a href=\"https:\/\/tradebrains.in\/get\/telegram\/\"><img decoding=\"async\" class=\"alignnone wp-image-101992\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/telegram-channel-300x119.png\" alt=\"\" width=\"148\" height=\"59\" \/><\/a> <a href=\"https:\/\/news.google.com\/publications\/CAAqBwgKMN3Epgswxc--Aw?hl=en-IN&amp;gl=IN&amp;ceid=IN%3Aen\"><img decoding=\"async\" class=\"alignnone wp-image-123430\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png\" alt=\"follow-on-google-news\" width=\"222\" height=\"61\" srcset=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png 300w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-150x41.png 150w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news.png 468w\" sizes=\"(max-width: 222px) 100vw, 222px\" \/><\/a><\/p>\n<\/div><p>NIFTY Pharma, the harbinger of the sectors that boomed during the Covid-19 pandemic has been down more than 12% since the start of this year. After its correction, market experts believe that the pharma and healthcare industry may be an attractive bet again.<\/p><div class=\"trade-content_7\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-2243727351\"><!-- Composite Start --> \r\n <div id=\"M923760ScriptRootC1549812\"> \r\n <\/div> \r\n <script src=\"https:\/\/jsc.mgid.com\/t\/r\/tradebrains.in.1549812.js\" async> \r\n <\/script> \r\n <!-- Composite End --><\/div><p>Here are three pharma stocks recommended by Sharekhan Securities to buy for an upside of more than 34%.&nbsp;<\/p><h4 class=\"wp-block-heading\"><strong>Divi\u2019s Labs<\/strong><\/h4><p>Battered by market sentiments despite its strong Q4 results, the stock has lost more than 18% of its value since the announcement of the results. The Hyderabad-based manufacturer and custom synthesizer of generic APIs, intermediates and nutraceutical ingredients saw 41% year-on-year (YoY) revenue growth to \u20b9 2,518 crores. EBITDA climbed 54 \u20b9 YoY to \u20b9 1,104 crores, while net profit scaled up 78% YoY to \u20b9 895 crores.<\/p><ul class=\"wp-block-list\"><li>CMP: \u20b9 3,486<\/li><li>Target Price: \u20b9 4,900<\/li><li>Upside: 40.56%<\/li><\/ul><h4 class=\"wp-block-heading\"><strong>Sanofi India<\/strong><\/h4><p>Sanofi India provides a variety of medicines for therapeutic areas such as cardiology, central nervous system, diabetes, thrombosis, and anti-histamines. Its standalone net income soared 63.39% to \u20b9 238.40 crores accompanied by a 2.49% decline in operating revenue to \u20b9 707 crores in Q1 ended March 2022 over the same period last year.<\/p><div class=\"trade-content_5\" id=\"trade-3230236545\"><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-4023722985638610\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<!-- in_content_2_news -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-4023722985638610\"\r\n     data-ad-slot=\"7925020301\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><\/div><ul class=\"wp-block-list\"><li>CMP: \u20b9 6,678<\/li><li>Target Price: \u20b9 9,250<\/li><li>Upside: 38.51%<\/li><\/ul><h4 class=\"wp-block-heading\" id=\"h-gland-pharma\"><strong>Gland Pharma<\/strong><\/h4><p>With its heavy cash balances and ample opportunities in the contract development and manufacturing space on the biologics front, Gland Pharma appears to be an attractive investment despite its more than 27% year-to-date decline.\u00a0<\/p><p>The net profit of the company rose 9.79% to \u20b9 285.90 crores in the quarter ended March 2022.<\/p><ul class=\"wp-block-list\"><li>CMP: \u20b9 2,798<\/li><li>Target Price: \u20b9 3,770<\/li><li>Upside: 34.74%<\/li><\/ul><h4 class=\"wp-block-heading\"><strong>Disclaimer<\/strong><\/h4><div class=\"wp-block-image\"><figure class=\"aligncenter size-full is-resized\"><img decoding=\"async\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/warning-disclaimer.png\" alt=\"\" class=\"wp-image-26306\" width=\"256\" height=\"256\"\/><\/figure><\/div><p><strong>The views and investment tips expressed by investment experts\/broking houses\/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.<\/strong><\/p><div class=\"trade-after-content\" id=\"trade-1016465755\"><div id=\"taboola-below-article-thumbnails\"><\/div>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({\r\n    mode: 'alternating-thumbnails-a',\r\n    container: 'taboola-below-article-thumbnails',\r\n    placement: 'Below Article Thumbnails',\r\n    target_type: 'mix'\r\n  });\r\n<\/script>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({flush: true});\r\n<\/script><\/div>","protected":false},"excerpt":{"rendered":"<p>NIFTY Pharma, the harbinger of the sectors that boomed during the Covid-19 pandemic has been down more than 12% since the start of this year. After its correction, market experts believe that the pharma and healthcare industry may be an attractive bet again. Here are three pharma stocks recommended by Sharekhan Securities to buy for [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":13573,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[1513,31],"tags":[4021,4023,992,3047,3046,4022,3157,2746,3227,2597,2599],"class_list":["post-47853","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-editor-pick","category-news","tag-divis-labs","tag-gland-pharma","tag-pharma-sector","tag-pharma-stocks","tag-pharma-stocks-to-buy","tag-sanofi-india","tag-stock-to-watch","tag-stocks-to-buy","tag-stocks-to-buy-in-2022","tag-stocks-to-watch","tag-stocks-to-watch-in-2022"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.5 (Yoast SEO v25.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Stock Recommendation: 3 Pharma Stocks with More than 34% Upside Potential - Trade Brains Features<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tradebrains.in\/features\/3-pharma-stocks-with-more-than-34-upside-potential\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Stock Recommendation: 3 Pharma Stocks with More than 34% Upside Potential\" \/>\n<meta property=\"og:description\" content=\"NIFTY Pharma, the harbinger of the sectors that boomed during the Covid-19 pandemic has been down more than 12% since the start of this year. After its correction, market experts believe that the pharma and healthcare industry may be an attractive bet again. Here are three pharma stocks recommended by Sharekhan Securities to buy for [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tradebrains.in\/features\/3-pharma-stocks-with-more-than-34-upside-potential\/\" \/>\n<meta property=\"og:site_name\" content=\"Trade Brains Features\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/TradeBrainsOfficial\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-12T07:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/01\/Markets-up-3-Cover-Image-.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"854\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Trade Brains\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Stock Recommendation: 3 Pharma Stocks with More than 34% Upside Potential\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/01\/Markets-up-3-Cover-Image-.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:site\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Trade Brains\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/tradebrains.in\/features\/3-pharma-stocks-with-more-than-34-upside-potential\/\",\"url\":\"https:\/\/tradebrains.in\/features\/3-pharma-stocks-with-more-than-34-upside-potential\/\",\"name\":\"Stock Recommendation: 3 Pharma Stocks with More than 34% Upside Potential - Trade Brains Features\",\"isPartOf\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/tradebrains.in\/features\/3-pharma-stocks-with-more-than-34-upside-potential\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/tradebrains.in\/features\/3-pharma-stocks-with-more-than-34-upside-potential\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/01\/Markets-up-3-Cover-Image-.jpg\",\"datePublished\":\"2022-06-12T07:00:00+00:00\",\"author\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\"},\"breadcrumb\":{\"@id\":\"https:\/\/tradebrains.in\/features\/3-pharma-stocks-with-more-than-34-upside-potential\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/tradebrains.in\/features\/3-pharma-stocks-with-more-than-34-upside-potential\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/3-pharma-stocks-with-more-than-34-upside-potential\/#primaryimage\",\"url\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/01\/Markets-up-3-Cover-Image-.jpg\",\"contentUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/01\/Markets-up-3-Cover-Image-.jpg\",\"width\":1280,\"height\":854,\"caption\":\"nifty Sensex\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/tradebrains.in\/features\/3-pharma-stocks-with-more-than-34-upside-potential\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/tradebrains.in\/features\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Stock Recommendation: 3 Pharma Stocks with More than 34% Upside Potential\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/tradebrains.in\/features\/#website\",\"url\":\"https:\/\/tradebrains.in\/features\/\",\"name\":\"Trade Brains\",\"description\":\"Stock Market NSE\/BSE Latest News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/tradebrains.in\/features\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\",\"name\":\"Trade Brains\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"caption\":\"Trade Brains\"},\"sameAs\":[\"http:\/\/tradebrains.in\/\"],\"url\":\"https:\/\/tradebrains.in\/features\/author\/trade-brains\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Stock Recommendation: 3 Pharma Stocks with More than 34% Upside Potential - Trade Brains Features","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tradebrains.in\/features\/3-pharma-stocks-with-more-than-34-upside-potential\/","og_locale":"en_US","og_type":"article","og_title":"Stock Recommendation: 3 Pharma Stocks with More than 34% Upside Potential","og_description":"NIFTY Pharma, the harbinger of the sectors that boomed during the Covid-19 pandemic has been down more than 12% since the start of this year. After its correction, market experts believe that the pharma and healthcare industry may be an attractive bet again. Here are three pharma stocks recommended by Sharekhan Securities to buy for [&hellip;]","og_url":"https:\/\/tradebrains.in\/features\/3-pharma-stocks-with-more-than-34-upside-potential\/","og_site_name":"Trade Brains Features","article_publisher":"https:\/\/www.facebook.com\/TradeBrainsOfficial\/","article_published_time":"2022-06-12T07:00:00+00:00","og_image":[{"width":1280,"height":854,"url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/01\/Markets-up-3-Cover-Image-.jpg","type":"image\/jpeg"}],"author":"Trade Brains","twitter_card":"summary_large_image","twitter_title":"Stock Recommendation: 3 Pharma Stocks with More than 34% Upside Potential","twitter_image":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/01\/Markets-up-3-Cover-Image-.jpg","twitter_creator":"@TradeBrainsGrp","twitter_site":"@TradeBrainsGrp","twitter_misc":{"Written by":"Trade Brains","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/tradebrains.in\/features\/3-pharma-stocks-with-more-than-34-upside-potential\/","url":"https:\/\/tradebrains.in\/features\/3-pharma-stocks-with-more-than-34-upside-potential\/","name":"Stock Recommendation: 3 Pharma Stocks with More than 34% Upside Potential - Trade Brains Features","isPartOf":{"@id":"https:\/\/tradebrains.in\/features\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tradebrains.in\/features\/3-pharma-stocks-with-more-than-34-upside-potential\/#primaryimage"},"image":{"@id":"https:\/\/tradebrains.in\/features\/3-pharma-stocks-with-more-than-34-upside-potential\/#primaryimage"},"thumbnailUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/01\/Markets-up-3-Cover-Image-.jpg","datePublished":"2022-06-12T07:00:00+00:00","author":{"@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666"},"breadcrumb":{"@id":"https:\/\/tradebrains.in\/features\/3-pharma-stocks-with-more-than-34-upside-potential\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tradebrains.in\/features\/3-pharma-stocks-with-more-than-34-upside-potential\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/3-pharma-stocks-with-more-than-34-upside-potential\/#primaryimage","url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/01\/Markets-up-3-Cover-Image-.jpg","contentUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/01\/Markets-up-3-Cover-Image-.jpg","width":1280,"height":854,"caption":"nifty Sensex"},{"@type":"BreadcrumbList","@id":"https:\/\/tradebrains.in\/features\/3-pharma-stocks-with-more-than-34-upside-potential\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/tradebrains.in\/features\/"},{"@type":"ListItem","position":2,"name":"Stock Recommendation: 3 Pharma Stocks with More than 34% Upside Potential"}]},{"@type":"WebSite","@id":"https:\/\/tradebrains.in\/features\/#website","url":"https:\/\/tradebrains.in\/features\/","name":"Trade Brains","description":"Stock Market NSE\/BSE Latest News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tradebrains.in\/features\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666","name":"Trade Brains","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","caption":"Trade Brains"},"sameAs":["http:\/\/tradebrains.in\/"],"url":"https:\/\/tradebrains.in\/features\/author\/trade-brains\/"}]}},"_links":{"self":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/47853","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/comments?post=47853"}],"version-history":[{"count":1,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/47853\/revisions"}],"predecessor-version":[{"id":47854,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/47853\/revisions\/47854"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media\/13573"}],"wp:attachment":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media?parent=47853"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/categories?post=47853"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/tags?post=47853"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}